Nathan A. Pennell, MD, PhD

Nathan A. Pennell, MD, PhD, discusses the significance of the FDA approval of taletrectinib for ROS1-positive non-small cell lung cancer.

Nathan A. Pennell, MD, PhD, discusses the importance of understanding the cost-effectiveness of osimertinib in non–small cell lung cancer.

Nathan A. Pennell, MD, PhD, discusses remaining challenges in non–small cell lung cancer.

Nathan A. Pennell, MD, PhD, discusses the evolution of targeting HER2 in lung cancer.

Nathan Pennell, MD, PhD, discusses the evolution of targeted therapies in the field of non–small cell lung cancer.

Nathan Pennell, MD, PhD, discusses challenges with next-generation sequencing in lung cancer.

Nathan A. Pennell, MD, PhD, discusses the considerations when choosing therapy for patients with lung cancer who need immediate therapy but have not received the results of their molecular testing.

Nathan A. Pennell, MD, PhD, discusses the benefits of liquid biopsies in lung cancer.

Nathan A. Pennell, MD, PhD, discusses the underutilization of genetic testing in lung cancer.

In the most recent decade, we have seen an acceleration of discovery in NSCLC, primarily driven by our understanding that there are many types of lung cancer.

Nathan A. Pennell, MD, PhD, director, Lung Cancer Medical Oncology Program, Cleveland Clinic Taussig Cancer Institute, discusses the cost-effectiveness of next-generation sequencing for patients with metastatic non–small cell lung cancer.